Your session is about to expire
← Back to Search
YIV-906 + Sorafenib for Hepatocellular Carcinoma
This trial is testing if YIV-906, an extract of four herbs, can help fight Hepatitis B associated advanced liver cancer when used with the standard-of-care treatment, sorafenib.
- Liver Cancer
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Find a Location
Who is running the clinical trial?
- You have serious or uncontrolled medical conditions that could affect your participation in the study.Participants categorized to stage B or C based on Barcelona Clinic Liver Cancer (BCLC) staging system.You currently have or recently had a problem with your immune system, mental health, or drug abuse that is not under control.You have a blockage in your intestines or a history of severe inflammation or surgery in your intestines.You have experienced bleeding, including from your stomach or intestines, within the past 4 weeks before starting treatment.You have cancer that has spread to your brain or the covering of your brain.You are someone who drinks alcohol regularly.You have received an organ transplant.You have taken traditional Chinese medicines within 14 days before starting the study treatment.You are expected to live for at least three more months.You are expected to live for at least 3 more months.You have advanced liver cancer that cannot be surgically removed and have already tried other treatments without success. Alternatively, you have liver cancer that has spread to other parts of your body.You have had an allergic reaction to the ingredients in YIV-906 before.You have liver cancer that cannot be removed by surgery and all other treatment options have been exhausted or are not suitable for you. Additionally, you may have cancer that has spread outside of the liver.You are currently taking a high dose of blood thinners like warfarin.You have received treatments such as chemotherapy, immunotherapy, targeted therapy, or a specific type of Chinese medicine called Cinobufacini for your cancer.
- Group 1: Sorafenib + YIV-906
- Group 2: Sorafenib + Placebo
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What other drugs have been studied alongside YIV-906+Sorafenib?
"Currently, there are 65 ongoing clinical trials studying the efficacy of YIV-906+Sorafenib. Out of those, 24 have reached Phase 3 testing. Most of these studies taking place in Taibei, Taiwan; though there are 2804 research sites for this medication globally."
Are recruitment efforts for this research still ongoing?
"The date on clinicaltrials.gov suggests that this study is still looking for patients to enroll. This trial was first announced on January 10th 2020 with the most recent update being from July 11th 2022."
What is YIV-906+Sorafenib generally prescribed for?
"YIV-906+Sorafenib is an effective treatment for progressive, metastatic radioactive iodine-refractory differentiated thyroid carcinoma (dtc) as well as other conditions such as gastrointestinal stromal tumors, leiomyosarcomad thyroid carcinoma (dtc) as well as other conditions such as gastrointestinal stromal tumors, leiomyosarcoma, and hemangiosarcoma."
Is it dangerous to take YIV-906+Sorafenib?
"There is limited data to support the safety of YIV-906+Sorafenib, as this medication is still in Phase 2 clinical trials."
With how many individuals is this experiment being conducted?
"That is correct. According to the latest information on clinicaltrials.gov, this trial is still recruiting patients. This particular study was first posted on 1/10/2020, and the website was updated as recently as 7/11/2022. The research team is looking for 125 people total, but they need to be at one of the two locations."
Who else is applying?
How old are they?
What portion of applicants met pre-screening criteria?
Share this study with friends